Abstract
Administration of interferons (IFNs) may induce antibodies that interfere with therapeutic efficacy. We have optimized and validated methods for large-scale economic screening. Sera from patients with relapsing-remitting multiple sclerosis (MS) were investigated for binding antibody (BAb) by protein-G affinity-chromatography radioimmunoassay and a commercially available enzyme immunoassay (EIA). Neutralizing antibody (NAb) was investigated by cytopathic effect assays (CEA) using both fixed amount and serially diluted sera. BAb correlated with log10-transformed titres obtained by EIA (r=0.70, P
Originalsprog | Engelsk |
---|---|
Tidsskrift | Multiple Sclerosis |
Vol/bind | 12 |
Udgave nummer | 1 |
Sider (fra-til) | 39-46 |
Antal sider | 8 |
ISSN | 1352-4585 |
Status | Udgivet - 1 feb. 2006 |